ISRG
Intuitive Surgical
$402.95
▼ 0.9%Updated Today 7:15 PM ET
▼ Down 20.2% over the last 12 months
Market Cap
$144.07B
P/E
48.66x
Forward P/E (est.)
40.24x
ROE
17.0%
Revenue Growth
21.4%
EPS Growth
20.9%
Profit Margin
28.1%
FCF Yield
1.3%
Debt / Equity
0x
ROIC
13.0%
Interest Coverage
—
Current Ratio
4.61x
Dividend Yield
—
Implied Growth (rev. DCF)
7.1%
Rating Score
68/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what ISRG's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. ISRG trades near $402.95, below its 50-day average ($439.73) and 200-day average ($490.69). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 41 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. ISRG's is $12.00 (~3.0% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month ISRG found buyers near $396.68 (support) and sellers near $447.57 (resistance); its 52-week range is $396.68–$603.88. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.7× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Intuitive Surgical (ISRG) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $144.07B.
In its latest reported year it generated about $10.06B in revenue and $2.86B in net profit.
Our model rates ISRG Favorable (68/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
15.2%
Revenue moved from $5.71B in 2021 to $10.06B in 2025, a 15.2% compound annual growth rate. The most recent year grew a strong 21.4% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
66.0%
Operating Margin
29.3%
Net Margin
28.4%
ROE
17.0%
Intuitive Surgical keeps about 28.1% of each sales dollar as net profit, with a 66.0% gross margin and 29.3% operating margin. Return on equity is 17.0% and return on invested capital about 13.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
0x
Leverage: debt-to-equity is 0.0x, with a current ratio of 4.6x. That is a conservative balance sheet — a cushion in downturns.
Operating CF
$3.03B
Free Cash Flow
$2.49B
FCF Margin
24.7%
In the latest year Intuitive Surgical produced about $3.03B of operating cash flow and $2.49B of free cash flow after capital spending. That is a free-cash-flow yield of about 1.3% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
48.66x
P/S
14.77x
P/B
10.99x
EV / EBITDA
—
ISRG trades at 48.7x trailing earnings (about 40.2x on estimated forward earnings), 14.8x sales, and 11.0x book value. Reverse-engineering today's price implies the market expects roughly 7.1% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How ISRG stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), ISRG ranks #10 of 59 by our overall rating. It trades at a premium versus the sector on earnings (48.7x P/E vs. 25.4x median) with a higher return on equity (17.0% vs. 14.9%) and faster revenue growth (21.4% vs. 7.9%).
P/E vs sector
48.7x
median 25.4x
ROE vs sector
17.0%
median 14.9%
Growth vs sector
21.4%
median 7.9%
Sector rank
#10
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$598.52 – $1,011.30
vs. $402.95 today · expected CAGR 8% – 20%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $12.18B | $14.74B | $17.83B | $21.57B | $26.11B |
| Net income | $3.41B | $4.13B | $4.99B | $6.04B | $7.31B |
| EPS | $9.63 | $11.65 | $14.10 | $17.06 | $20.64 |
| Share price (low) | $279.22 | $337.85 | $408.80 | $494.65 | $598.52 |
| Share price (high) | $471.78 | $570.85 | $690.73 | $835.78 | $1,011.30 |
| CAGR (low–high) | -31% / 17% | -8% / 19% | 0% / 20% | 5% / 20% | 8% / 20% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for ISRG:
- Revenue is growing 21.4% a year, a sign of real demand.
- High net margins (28.1%) point to pricing power or efficiency.
- Strong return on equity (17.0%) shows capital is put to work well.
- A conservative balance sheet (debt/equity 0.0x) lowers risk.
- Our model's overall read is Favorable (68/100).
The case against ISRG:
- A rich 48.7x earnings multiple prices in a lot of growth.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 48.7x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Intuitive Surgical is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 48.7x earnings, which our model scores Favorable (68/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.